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Abstract: Hyaluronic acid (HA) has been widely used for viscosupplementation of diseased or 
aged articular joints. However, recent investigations have revealed the active anti-inflammatory 
or chondroprotective effect of HA, suggesting its potential role in attenuation of joint damage. 
In particular, interactions between HA and other inflammatory mediators are attracting inter-
est. This review summarizes several aspects of recent investigations of the anti-inflammatory 
effects of HA in arthritis.
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Introduction
Intra-articular administration of hyaluronic acid (HA; hyaluronan) is a widely applied 
treatment for osteoarthritis (OA) (reviewed by Simon and Strand).1 Although HA 
injection provides relief from pain, albeit transiently, its mechanism of action has not 
been fully clarified. In a recent recommendation on the management of hip and knee 
OA by the Osteoarthritis Research Society International (OARSI),2 the strength of 
recommendation (SOR) of intra-articular HA was calculated to be relatively low (64%), 
whereas that of nonsteroidal anti-inflammatory drugs (NSAIDs) for oral administration 
as analgesics was 92%–93%.
The effect of HA in OA has often been attributed to its potential use in viscosupple-
mentation, ie, supplementation of viscosity; however, the benefits of HA from “some 
other action and not by its biomechanical properties” is also suggested (reviewed by 
Neustadt and colleagues).3 More specifically, a direct effect of HA against inflamma-
tion or cartilage degradation in OA has also been suggested.
In addition to its use in OA, intra-articular injection of HA has been used in patients 
with inflammatory arthritis such as rheumatoid arthritis (RA). In some reports, it is 
indicated that HA has beneficial effects on inflammatory arthritis.4–6
This study briefly reviews the recent findings related to the function of HA, focusing 
on its reported effects in chondrocytes, not only in supplementing viscosity, but also as a 
potential anti-inflammatory anti-arthritic agent. Since it is well-known that oligosaccharide 
hyaluronan is inversely involved in inflammation,7 whenever HA is mentioned in this 
paper, it should be understood that the reference is to high molecular weight hyaluronan.
Biochemistry of HA
Hyaluronic acid is a polysaccharide composed of repeating disaccharide units, ie, 
1,4-glucuronic acid (GlcUA) and 1,3-N-acetylglucosamine (GlcNAC). HA belongs International Journal of General Medicine 2009:2 78
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to the group of glycosaminoglycans, but unlike chondroitin 
sulfate or keratan sulfate, HA is not sulfated. HA is synthe-
sized by bioactivity of hyaluronan synthase (HAS), which 
has been reported to have three isoforms (HAS1, HAS2, and 
HAS3) in humans.8
HA is widely distributed but mainly localized to the 
extracellular matrix and body fluid. It contributes to the 
viscoelasticity of the fluid and elasticity in connective tissues, 
which absorb mechanical stress, for example, between car-
tilage and cartilage surfaces.3
In addition to this property of providing viscoelasticity, 
recent investigations have continued to reveal the variety of 
actions of HA on cartilage. For example, in normal diarthrodial 
joints, HA not only works as a mechanical/physical barrier, 
but also has anti-inflammatory and analgesic functions.3 As 
for pain suppression, it has been shown that HA attenuates 
prostaglandin- or bradykinin-induced pain in experimental 
OA animals.9,10
HA binds to the signal-transducing receptor molecules 
CD44 and receptor for HA-mediated motility (RHAMM; 
reviewed by Taylor and colleagues).11 In this regard, CD44 is 
the primary receptor of HA, and has also been found to bind 
with other matrix components, including collagen, chondroi-
tin sulphate, and osteopontin.11–13 Binding of the components 
to CD44 leads to modulation of cellular functions;14–16 for 
example, HA is reported to inhibit proteoglycan degradation 
and anti-Fas-induced apoptosis of chondrocytes through 
CD44 expressed on the cells.17,18
HA suppresses inflammatory 
responses in articular joints
HA suppresses MMPs and ADAMTS
In inflammatory or degenerative joints, cartilage matrix 
is degraded by the action of an array of proteinases. In 
particular, the families of matrix metalloproteinases (MMP) 
and a disintegrin and metalloproteinase with thrombospondin 
motifs (ADAMTS) are mainly responsible for cartilage deg-
radation. More specifically, the collagenases (MMP-1 and 
MMP-13) and stromelysin-1 (MMP-3) play a pivotal role in 
collagen degradation, whereas the aggrecanases (ADAMTS) 
induce aggrecan degradation. These proteinases are often 
induced by inflammatory stimuli, such as interleukin-1 (IL-1) 
or tumor necrosis factor-α (TNF-α), which are activated by 
inflammation or mechanical or physical stress in joints.19,20 
Subsequently, in an inflamed joint, cartilage exposed to 
the induced ADAMTS-4 and ADAMTS-5 would release 
HA, indicating deterioration of matrix integrity;21 this loss 
of HA from the cartilage matrix is thought to result in the 
progression of cartilage degradation. On the other hand, it 
has been demonstrated that HA can enhance synthesis of 
chondroitin sulfate and proteoglycans,22,23 and reduce the 
production and activity of MMPs and ADAMTS.5,24,25
IL-1 is considered to be the dominant catabolic cytokine 
present in the inflamed articular joints. In this regard, HA is 
reported to counteract the catabolic process induced by IL-1. 
For example, Fioravanti and colleagues stimulated human 
chondrocytes under hydrostatic pressure and showed that HA 
(MW 500–730 kDa) abrogates a decrease in proteoglycan 
and an increase in nitric oxide (NO) levels, both induced by 
IL-1. In a study by Karna and colleagues, HA (500–730 kDa) 
was found to counteract the effect of IL-1, as HA inhibited 
IL-1-induced downregulation of type II collagen mRNA 
expression.26 Julovi and colleagues27 used 800-kDa HA to 
assess the inhibitory effect of HA on IL-1β-induced MMPs 
in cartilage and found that the 800-kDa HA penetrated 
cartilage tissue, localized in the pericellular matrix around 
chondrocytes, and bound with CD44 on chondrocytes, lead-
ing to the suppression of IL-1β-stimulated MMP production 
by chondrocytes. In this context, we found that HA (800 kDa 
and 1900 kDa) suppressed IL-1-induced MMP-1 production 
both at protein and mRNA levels in cultured human chon-
drocytes, and this effect was cancelled by treatment with 
anti-CD44 antibody.28
As for synovial fibroblasts, Shimizu and colleagues29 
reported that HA inhibited TNF-α- and IL-1-induced MMP-1 
production from rheumatoid synovial fibroblasts. For this 
effect, HA was suggested to bind with CD44 expressed 
in synovial fibroblasts. More recently, the interaction 
between synovial fibroblasts and HA via intracellular adhe-
sion molecule-1 (ICAM-1) was reported by Hiramitsu and 
colleagues.29 The mechanism of this inhibition was speculated 
to occur through HA binding to ICAM-1, leading to down-
regulation of nuclear factor-κB (NF-κB) and p38 mitogen-
activated protein kinase (MAPK) phosphorylation.
In addition to the effects shown against MMPs, a recent 
report by Yatabe and colleagues indicated the inhibition of 
ADAMTS4 (aggrecanase-1) expression in human chondro-
cytes by HA (2700 kDa) through the CD44 and ICAM-1 
signaling pathways.25 These findings collectively suggest 
a therapeutic potential of HA against matrix breakdown in 
arthritic cartilage.
Plasmin/plasminogen system and HA
Fibrinolysis is one of the major pathological changes occur-
ring in arthritic joints, in which the plasminogen system is 
known to play a key role. The balance between plasminogen International Journal of General Medicine 2009:2 79
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activator (PA) and plasminogen activator inhibitor (PAI) 
determines the direction in which plasminogen is activated 
into plasmin, which in turn further promotes fibrinolysis 
by activating proteinases, including gelatinases and other 
MMPs. PA occurs in two forms: urokinase-type PA (uPA) 
and tissue-type PA (tPA).
It has been suggested that hyaluronan modulates the 
PA system in articular joints. For example, Nonaka and 
colleagues30 reported that HA suppressed the secretion of 
u-PA and PAI-1 from OA synovial fibroblasts. Further, it 
was found that the receptor for u-PA (u-PAR) was expressed 
in the synovium in both OA and RA and that the expression 
was attenuated by treatment with HA.30 These results sug-
gested that HA could suppress fibrinolytic activity mediated 
by the uPA and uPAR systems. More recently, Hsieh et al 
measured the levels of MMP-2, MMP-9, u-PA, and PAI-1 
in a series of chondral, meniscal, and synovial cultures of 
early OA after treatment with or without three HA products 
with different molecular weights (MW), and demonstrated 
that all of the HA products could decrease the secretion of 
MMP-2 and MMP-9. They suggested that HA with high 
MW might be more effective in inhibiting MMP-2, MMP-9, 
u-PA, and PAI-1 expression.31 Further investigation on the 
crosstalk between PA/PAI and HA would provide important 
clues to the protection of cartilage degradation by these 
proteinases.
Hyaluronan and cyclooxygenase
Acidic NSAIDs are a major subset of anti-inflammatory 
drugs that inhibit the activity of cyclooxygenase (COX), 
leading to suppression of prostaglandins and leukotrienes 
in inflamed tissue. In this regard, interaction has been 
demonstrated between HA or its fragment and COX-2 
expression in a variety of cells.32–35 Several studies showed 
upregulation of COX-2 expression by HA. For example, 
HA (200-kDa) was reported to increase the expression of 
glomerular COX-2 in rat renal glomerular cells34 and in 
human vascular endothelial cells,36 respectively. The effect 
of HA has been reported to be mimicked by an engagement 
of CD44 (an HA receptor).35,36 Further, Stuhlmeier reported 
prostaglandin E2(PGE2) as a potent activator of HAS1 
in IL-1-treated type-B-synoviocytes.37 In that study, the 
author tested a series of eicosanoids and found that PGE2, 
and to a lesser extent, PGI2 and thromboxane A2 analogues 
activated HAS1 expression in synoviocytes after IL-1 
treatment, whereas the lipoxygenase product leukotriene 
B4 had no effect on HAS1 induction. Therefore, HA may 
upregulate COX-2, causing the activated COX-2 to induce 
PGE2, which would then activate HAS1 through a positive 
feedback mechanism (Figure 1). Conversely, Mitsui and 
colleagues demonstrated an inhibitory effect of HA on the 
expression of COX-2 mRNA in IL-1-stimulated subacro-
mial synovial fibroblasts.33 In that study, however, HA 
with a molecular weight of 90 × 104 was used; therefore, 
the different effect of HA might have been due to the dif-
ference in the molecular weight. In addition, Kinugasa 
and colleagues40 reported that inhibition of COX-2 using 
a COX inhibitor or COX-2 antisense oligonucleotide in 
a tumor cell line resulted in downregulation of CD44 
expression.38
Collectively, the HAS/HA system and COX/PG system 
may have a regulatory network via CD44, which would 
be regulated differently by each HA component present 
in each cell type, and further modulated by the presence 
of inflammatory cytokines and mediators (Figure 1). Still, 
inconsistency among studies concerning the interaction 
between HA and COX/PG may also, at least in part, be due 
to the expression or activation of HAS isoforms (HAS1-3), 
the expression pattern of prostanoid receptors, or the amount 
of concomitant stimuli by other inflammatory mediators 
such as IL-1. For example, isoforms of HAS or EP recep-
tors are expressed and function differentially among tissues 
and cells.8,39 Elucidation of the interaction between HA 
and COX systems in articular chondrocytes would give 
important information about the clinical application of HA 
with simultaneous clinical use of NSAIDs, and may clarify 
the possible beneficial effects of HA with larger molecular 
weight in this regard.
Conclusions
Although articular injection of HA is frequently used in the 
treatment of arthritic conditions, the precise mechanism 
by which HA suppresses degradation of cartilage or intra-
articular inflammation is still under vigorous investigation. 
A disease-modifying effect of HA has been suggested 
by some in vitro studies; however, there has been little 
clinical evidence thus far. Understanding the wide array 
of signaling pathways of anti-inflammatory effects by HA 
will encourage novel anti-degradation strategies for both 
inflammatory and degenerative arthritides, using HA in 
combination with other disease-modifying anti-rheumatic 
drugs and/or NSAIDs.
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